The patent expiry on several big-selling drugs stretches through 2016, but the biggest drugs will have lost their patent protection by next year. Mylan, one of the world's largest generic drugmakers with more than 1,100 products, currently derives about 16 percent of revenue from its specialty drug business -- which involves the development of branded injectable products, such as EpiPen, its anti-allergen delivery product. Third-quarter net income rose to $211.3 million or 51 cents per share, from $156.7 million, or 36 cents per share, a year earlier. Excluding one-off items, Mylan earned 83 cents per share, beating Wall Street estimates of 77 cents per share, according to Thomson Reuters I/B/E/S. Total revenue rose nearly 15 percent to $1.81 billion, but fell short of analysts' expectations of $1.85 billion. Sales in North America rose 19.2 percent to $837 million.